Efficacy, safety and persistence of Ustekinumab versus Infliximab in bionaive patients with moderate to severe Crohn disease patients: a real world experience
BACKGROUND AND AIM: Ustekinumab was licenced for treatment of moderate to severe Crohn disease (CD) in Malaysia since March 2020 while Infliximab is a well-established treatment for moderate to severe CD. Our objective is to look at real- world data on efficacy, safety and persistence of Ustekinumab...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Proceeding Paper |
| Language: | en |
| Published: |
2022
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/99667/3/99667_efficacy_and%20safety%20of%20per-oral.pdf http://irep.iium.edu.my/99667/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|